ArticleCancer causes & control : CCC2014
Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986-2007.
Article in Cancer causes & control : CCC, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Domperidone Induces Apoptosis through Suppression of STAT3 Signaling in Human Renal Cancer Caki-2 Cells.Journal of cancer prevention · 2025Article
- Impact of the COVID-19 pandemic on diagnosis of renal cell carcinoma and disease stage at presentation.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- The impact of robotic surgery access on the management of patients with clinical stage I kidney tumors.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- Development and verification of a deep learning-based mJournal of cancer research and clinical oncology · 2023Article
- The Impact of COVID-19 on New Kidney Cancer Diagnosis: Stage and Treatment in Northern Italy.International journal of environmental research and public health · 2023Article
- Trends in Incidence and Mortality of Kidney Cancer in a Northern Italian Province: An Update to 2020.Biology · 2022Article
- Incidence trends for twelve cancers in younger adults-a rapid review.British journal of cancer · 2022Review
- Role of main RNA modifications in cancer: NSignal transduction and targeted therapy · 2022Review
- A novel ferroptosis-related gene signature associated with cell cycle for prognosis prediction in patients with clear cell renal cell carcinoma.BMC cancer · 2022Article
- The Early Diagnostic and Prognostic Value of BIRC5 in Clear-Cell Renal Cell Carcinoma Based on the Cancer Genome Atlas Data.Urologia internationalis · 2022Article
- Identification of a Necroptosis-Related Prognostic Index and Associated Regulatory Axis in Kidney Renal Clear Cell Carcinoma.International journal of general medicine · 2022Article
- Kidney injury molecule-1 inhibits metastasis of renal cell carcinoma.Scientific reports · 2021Article
- The value ofCanadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- m6A Modification: A Double-Edged Sword in Tumor Development.Frontiers in oncology · 2021Review
- SOX17 Antagonizes the WNT Signaling Pathway and is Epigenetically Inactivated in Clear-Cell Renal Cell Carcinoma.OncoTargets and therapy · 2021Article
- The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma.BMC cancer · 2020Article
- Kidney cancer survivorship care: Patient experiences in a Canadian setting.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Article
- Age-period-cohort analysis of kidney cancer deaths attributable to high body-mass index in China and U.S. adults.BMC public health · 2020Article
- A Novel mFrontiers in cell and developmental biology · 2020Article
- Trends in cancer incidence in Uruguay: 2002 -2015.Colombia medica (Cali, Colombia) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeKidney cancer is one of the fastest rising cancers worldwide. We aimed to examine the trends in incidence, mortality, and survival for this cancer in Canada.
methodsIncidence data for kidney cancer for 1986-2010 were from the Canadian Cancer Registry and the National Cancer Incidence Reporting System. These data were only available up to 2007 for the province of Quebec and consequently for the same year nationally, for Canada. Mortality data for 1986-2009 were from the Canadian Vital Statistics Death Database. Changes in age-standardized rates were analyzed by Joinpoint regression. Incidence rates were projected to 2025 using a Nordpred age-period-cohort model. Five-year relative survival ratios (RSR) were analyzed for 2004-2008 and earlier periods.
resultsBetween 1986 and 2007, the age-standardized incidence rate (ASIR) per 100,000 rose from 13.4 to 17.9 in males and 7.7 to 10.3 in females. Annual increases in ASIR were greatest for age groups <65 years (males) and ≥65 years (females). The ASIRs increased significantly over time in both sexes for renal cell carcinoma (RCC) but not for other kidney cancer types. RCC rates are projected to increase until at least 2025. Mortality rates decreased only slightly in each sex since 1986 (0.4%/year in males; 0.8%/year in females). The 5-year RSR for kidney cancer was 68% but differed largely by morphology and age, and has increased slightly over time.
conclusionsThe incidence rate of kidney cancer in Canada has risen since at least 1986, led largely by RCC. Increasing detection of incidental tumors, and growing obesity and hypertension rates are possible factors associated with this increase. Greater prevention of modifiable risk factors for kidney cancer is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.